| Filed On | Filing |
|---|---|
| 28 Oct 2026 |
8-K: Results of Operations and Financial Condition
WASHINGTON – October 28, 2026 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2026. |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
WASHINGTON – August 5, 2026 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2026. |
| 05 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
At the 2026 annual meeting of stockholders of Vanda Pharmaceuticals Inc. (the “Company”) held on June 4, 2026 (the “Annual Meeting”), the following proposals were submitted to the stockholders of the Company: |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition
WASHINGTON – May 6, 2026 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2026. |
| 22 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
WASHINGTON, April 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the appointment of Charles Duncan, Ph.D. to its Board of Directors effective April 22, 2026. Following Dr. Duncan’s appointment,... |
| 02 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 10 Mar 2026 |
8-K: Regulation FD Disclosure
On March 10, 2026, Mihael Polymeropoulos, M.D., President, Chief Executive Officer and Chairman of the Board of Vanda Pharmaceuticals Inc. (“Vanda”), appeared on Mornings with Maria on Fox Business and discussed Vanda’s pricing and comme... |
| 23 Feb 2026 |
8-K: Other Events
Vanda Pharmaceuticals Announces FDA Approval of BYSANTITM (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation |
| 19 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
VANDA PHARMACEUTICALS INC.AMENDED AND RESTATED 2016 EQUITY INCENTIVE PLAN:NOTICE OF PERFORMANCE RESTRICTED STOCK UNIT AWARD |
| 11 Feb 2026 |
8-K: Results of Operations and Financial Condition
WASHINGTON – February 11, 2026 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2025. |
| 08 Jan 2026 |
8-K: Other Events
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder |
| 31 Dec 2025 |
8-K: Other Events
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness |
| 04 Dec 2025 |
8-K: Other Events
WASHINGTON, Dec. 4, 2025 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on protocol VP-VLY-686-3403, which until today limite... |
| 28 Nov 2025 |
8-K: Other Events
WASHINGTON, Nov. 28, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced the following updates regarding tradipitant for motion sickness: |
| 29 Oct 2025 |
8-K: Results of Operations and Financial Condition
WASHINGTON – October 29, 2025 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2025. |
| 01 Oct 2025 |
8-K: Other Events
Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration |
| 31 Jul 2025 |
8-K: Results of Operations and Financial Condition
WASHINGTON – July 31, 2025 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2025. |
| 05 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
At the 2025 annual meeting of stockholders of Vanda Pharmaceuticals Inc. (the “Company”) held on June 5, 2025 (the “Annual Meeting”), the following proposals were submitted to the stockholders of the Company: |
| 07 May 2025 |
8-K: Results of Operations and Financial Condition
WASHINGTON – May 7, 2025 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2025. |
| 17 Mar 2025 |
8-K: Regulation FD Disclosure
On March 14, 2025, Vanda Pharmaceuticals Inc. (“Vanda”) issued a post on the social media platform X announcing that the U.S. Food and Drug Administration (the “FDA”) has accepted for filing Vanda’s new drug application for tradipitant f... |
Loading...